TREATMENT PROFILE AND SURVIVAL ANALYSIS ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) COVID-19 PATIENTS

MICHAEL; DIANA LAILA RAMATILLAH

doi:10.22159/ijap.2022.v14s2.44750

Authors

MICHAEL Faculty Pharmacy, Universitas 17 Agustus 1945 Jakarta, Sunter Agung, 14350 Tanjung Priok, North Jakarta, Indonesia
DIANA LAILA RAMATILLAH Faculty Pharmacy, Universitas 17 Agustus 1945 Jakarta, Sunter Agung, 14350 Tanjung Priok, North Jakarta, Indonesia

DOI:

https://doi.org/10.22159/ijap.2022.v14s2.44750

Keywords:

Covid-19, treatment, Survival rate, Antiviral, Antibacterial

Abstract

Objective of the review was to evaluate the correlation between treatment profile and survival analysis among Acute Respiratory Distress Syndrome (ARDS) covid-19 patients. Journals were searched from Google scholar, Elsevier and Pubmed with references from 2018 to 2021. Hydroxychloroquine and favipiravir has a good outcome in treating severe to critical illness patients. Ivermectin has a better output on treating mild to moderate symptoms covid-19 but further study is required to know the outcome from treating severe to critical illness. Oseltamivir only works on mild cases of covid-19, early-onset therapy on patient covid-19 can reduce the time of fever. An antibacterial is applied on the covid-19 patients with pneumonia and for cytokine storm patients required tocilizumab on therapy. Severe to critical cases of covid-19 can be given corticosteroid. Lopinavir/ritonavir and ribavirin have a poor antiviral activity against SARS-CoV-2. In conclusion, for severe to critical illness required hydroxychloroquine or favipiravir as antiviral agent plus antibacterial agent, if cytokine storm is developed tocilizumab can be given. For mild to moderate symptoms can be given oseltamivir or ivermectin, if there is a sign of bacterial infection (pneumonia) an antibacterial agent can be given.

Downloads

Download data is not yet available.

References

Sunggoro AJ, Purwanto I, Hasan M. Trombosis pada corona virus disease (COVID-19). J Kedokteran Syiah Kuala. 2020 Dec 1;20(3). doi: 10.24815/jks.v20i3.18689.

Shereen MA, Khan S, Kazmi A, Bashir N, Siddique R. COVID-19 infection: origin, transmission, and characteristics of human coronaviruses. J Adv Res. 2020;24:91-8. doi: 10.1016/j.jare.2020.03.005, PMID 32257431.

Correale P, Caracciolo M, Bilotta F, Conte M, Cuzzola M, Falcone C, Mangano C, Falzea AC, Iuliano E, Morabito A, Foti G, Armentano A, Caraglia M, De Lorenzo A, Sitkovsky M, Macheda S. Therapeutic effects of adenosine in high flow 21% oxygen aereosol in patients with Covid19-pneumonia. PLOS ONE. 2020 Oct 1;15(10):e0239692. doi: 10.1371/journal.pone.0239692, PMID 33031409.

Gee S, Gaughran F, MacCabe J, Shergill S, Whiskey E, Taylor D. Management of clozapine treatment during the COVID-19 pandemic. Ther Adv Psychopharmacol. 2020 Jan;10:2045125320928167. doi: 10.1177/ 2045125320928167, PMID 32542111.

Health Organization W. Guideline Therapeutics and COVID-19: living guideline; 2021.

Menteri K. Kesehatan republik indonesia. Available from: https://covid19.go.id/storage/app/media/Regulasi/2021/Agustus/kmk-no-hk0107-menkes-5671-2021-ttg-manajemen-klinis-tata-laksana-covid-19-di-fasilitas-pelayanan-kesehatan-signed-1.pdf. [Last accessed on 13 Dec 2021].

WHO-2019-nCoV-clinical-2020.4-chi. Available from: https://apps.who.int/iris/bitstream/handle/10665/331446/WHO-2019-nCoV-clinical-2020.4-chi.pdf. [Last accessed on 13 Dec 2021]

Keyaerts E, Vijgen L, Maes P, Neyts J, van Ranst M. In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine. Biochem Biophys Res Commun. 2004 Oct 8;323(1):264-8. doi: 10.1016/j.bbrc.2004.08.085, PMID 15351731.

Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Rollin PE, Ksiazek TG, Seidah NG, Nichol ST. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J. 2005 Aug 22;2:69. doi: 10.1186/1743-422X-2-69, PMID 16115318.

Catteau L, Dauby N, Montourcy M, Bottieau E, Hautekiet J, Goetghebeur E, van Ierssel S, Duysburgh E, Van Oyen H, Wyndham Thomas C, Van Beckhoven D, Belgian Collaborative Group on COVID-19 Hospital Surveillance. Low-dose hydroxychloroquine therapy and mortality in hospitalized patients with COVID-19: a nationwide observational study of 8075 participants. Int J Antimicrob Agents. 2020 Oct 1;56(4):106144. doi: 10.1016/j.ijantimicag.2020.106144, PMID 32853673.

Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R. Effects of chloroquine on viral infections: an old drug against today’s diseases? Lancet Infect Dis. 2003 Nov;3(11):722-7. doi: 10.1016/s1473-3099(03)00806-5, PMID 14592603.

Hu B, Huang S, Yin L. The cytokine storm and COVID-19. J Med Virol. 2021;93(1):250-6. doi: 10.1002/jmv.26232, PMID 32592501.

Mehta Y, Dixit SB, Zirpe KG, Ansari AS. Cytokine storm in novel coronavirus disease (COVID-19): Expert management considerations. Vol. 24. Indian Journal of Critical Care Medicine. Jaypee Brothers Medical Publishers (P) Ltd; 2020. p. 429–34.

Price CC, Altice FL, Shyr Y, Koff A, Pischel L, Goshua G, Azar MM, Mcmanus D, Chen SC, Gleeson SE, Britto CJ, Azmy V, Kaman K, Gaston DC, Davis M, Burrello T, Harris Z, Villanueva MS, Aoun-Barakat L, Kang I, Seropian S, Chupp G, Bucala R, Kaminski N, Lee AI, LoRusso PM, Topal JE, Dela Cruz C, Malinis M. Tocilizumab treatment for cytokine release syndrome in hospitalized patients with coronavirus Disease 2019: survival and clinical outcomes. Chest. 2020 Oct 1;158(4):1397-408. doi: 10.1016/j.chest.2020.06.006, PMID 32553536.

Xu X, Han M, Li T, Sun W, Wang D, Fu B, Zhou Y, Zheng X, Yang Y, Li X, Zhang X, Pan A, Wei H. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci USA. 2020 May 19;117(20):10970-5. doi: 10.1073/ pnas.2005615117, PMID 32350134.

Ramatillah DL, Isnaini S. Treatment profiles and clinical outcomes of COVID-19 patients at a private hospital in Jakarta. PLOS ONE. 2021 Apr 1;16(4) (Apr 4):e0250147. doi: 10.1371/journal.pone.0250147, PMID 33861777.

Davido B, Boussaid G, Vaugier I, Lansaman T, Bouchand F, Lawrence C, Alvarez JC, Moine P, Perronne V, Barbot F, Saleh Mghir A, Perronne C, Annane D, De Truchis P, COVID-19 RPC Team. Impact of medical care, including use of anti-infective agents, on prognosis of COVID-19 hospitalized patients over time. Int J Antimicrob Agents. 2020 Oct 1;56(4):106129. doi: 10.1016/j.ijantimicag.2020.106129, PMID 32755653.

Chiba S. Effect of early oseltamivir on outpatients without hypoxia with suspected COVID-19. Wien Klin Wochenschr. 2021 Apr 1;133(7-8):292-7. doi: 10.1007/s00508-020-01780-0, PMID 33296027.

Khamis F, Al Naabi H, Al Lawati A, Ambusaidi Z, Al Sharji M, Al Barwani U, Pandak N, Al Balushi Z, Al Bahrani M, Al Salmi I, Al-Zakwani I. Randomized controlled open label trial on the use of favipiravir combined with inhaled interferon beta-1b in hospitalized patients with moderate to severe COVID-19 pneumonia. Int J Infect Dis. 2021 Jan 1;102:538-43. doi: 10.1016/j.ijid.2020.11.008, PMID 33181328.

Tong S, Su Y, Yu Y, Wu C, Chen J, Wang S, Jiang J. Ribavirin therapy for severe COVID-19: a retrospective cohort study. Int J Antimicrob Agents. 2020 Sep 1;56(3):106114. doi: 10.1016/j.ijantimicag.2020.106114, PMID 32712334.

Bani Sadr F, Hentzien M, Pascard M, N’Guyen Y, Servettaz A, Andreoletti L, Kanagaratnam L, Jolly D. Corticosteroid therapy for patients with COVID-19 pneumonia: a before-after study. Int J Antimicrob Agents. 2020 Aug 1;56(2):106077. doi: 10.1016/j.ijantimicag.2020.106077, PMID 32634602.

Corticosteroids for COVID-19; 2020. Available from: https://www.who.int/publications/i/item/WHO-2019-nCoV-Corticosteroids-2020.1. [Last accessed on 22 Dec 2021]

Dexamethasone in hospitalized patients with covid-19. N Engl J Med. 2021 Feb 25;384(8):693-704. doi: 10.1056/ NEJMoa2021436.

Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020 Jun 1;178:104787. doi: 10.1016/j.antiviral.2020.104787, PMID 32251768.

Chowdhury ATMM, Shahbaz M, Karim MR, Islam J, Guo D, He S. A randomized trial of ivermectin-doxycycline and hydroxychloroquine-azithromycin therapy on COVID19 patients; 2020.

Title EB O. Ivermectin shows clinical benefits in mild to moderate COVID19: A randomised controlled double blind dose-response study in Lagos. doi: 10.1101/ 2021.01.05.21249131.

Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, Ruan L, Song B, Cai Y, Wei M, Li X, Xia J, Chen N, Xiang J, Yu T, Bai T, Xie X, Zhang L, Li C, Yuan Y, Chen H, Li H, Huang H, Tu S, Gong F, Liu Y, Wei Y, Dong C, Zhou F, Gu X, Xu J, Liu Z, Zhang Y, Li H, Shang L, Wang K, Li K, Zhou X, Dong X, Qu Z, Lu S, Hu X, Ruan S, Luo S, Wu J, Peng L, Cheng F, Pan L, Zou J, Jia C, Wang J, Liu X, Wang S, Wu X, Ge Q, He J, Zhan H, Qiu F, Guo L, Huang C, Jaki T, Hayden FG, Horby PW, Zhang D, Wang C. A trial of lopinavir–ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020 May 7;382(19):1787-99. doi: 10.1056/NEJMoa2001282, PMID 32187464.

Zhu Z, Lu Z, Xu T, Chen C, Yang G, Zha T, Lu J, Xue Y. Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19. J Infect. 2020 Jul 1;81(1):e21-3. doi: 10.1016/j.jinf.2020.03.060, PMID 32283143.

Ramatillah DL, Gan SH, Sulaiman SAS, Puja D, Abubakar U, Jaber AAS, Lukas S, Jusnita N. Evaluation of treatment outcome for pneumonia among pre-vaccinated COVID-19 Patients with/without comorbidity in a Public Hospital in Bengkulu, Indonesia. Vaccines (Basel). 2021;9(12). doi: 10.3390/vaccines9121411, PMID 34960157.

Clinical efficacy of lopinavir/ritonavir in the treatment of coronavirus disease 2019 [internet]. p. uniroma1. Italianist. Available from: https://web/spec_medint/sites/default/ files/3390-3396.pdf. [Last accessed on 23 Dec 2021].